Market Herald logo


Be the first with the news that moves the market
Sydney cancer immunotherapy research company, Imugene has presented positive vaccine trial results at the Annual American Association for Cancer Research. The results were released after a trial period on a genetically identical mouse-model subject with HER-2+ breast cancer. B-cell cancer growth was inhibited in the test subject after implementation of the newly developed mimitope programmed cell death protein (PD-1). The PD-1 elicited an antibody response in the mouse that inhibited growth of the cancer tumor. Imugene collaborated with the Medical University of Vienna at the Annual American during the trial tests. Please read the announcement attached.
IMU by the numbers
More From The Market Herald
icetana Limited, ICE - CEO, Matthew Macfarlane

" icetana Limited (ASX:ICE) signs Memorandum of Understanding with Threat Protect (ASX:TPS)

icetana Limited (ICE) has signed a memorandum of understanding with Threat Protect Australia (TPS).
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Envirosuite (ASX:EVS) - CEO, Jason Cooper

" Envirosuite (ASX:EVS) successfully raises $10.5m

Environmental solutions company Envirosuite (EVS) has successfully completed its institutional placement to raise $10.5 million.